Mike Thompson, MD, PhD, FASCO

@mtmdphd

#MedSky - VP Clinical Partnerships @TempusAI #PrecisionMedicine #mmsm #lymsm #CCC19 @COVID19nCCC @ASCO COI: https://coi.asco.org/share/RBB-TT6R/Michael

Milwaukee, WI

Joined September 2010

4KFollowing

23KFollowers

Pinned

Mike Thompson, MD, PhD, FASCO@mtmdphd · Jun 4

Myeloma / Plasma Cell Dyscrasia ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd - Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani

mtmdphd's tweet image. Myeloma / Plasma Cell Dyscrasia ~ #ASCO25Top10 (or so) #mmsm #mmMRD #ASCO25 - @mtmdphd
- Update: 6/3/25 - cc @grpetersen1 - @HadidiSamer @AuclairDan @RahulBanerjeeMD @myelomaMD @bdermanmd @szusmani

3.0K

Pinned

Mike Thompson, MD, PhD, FASCO@mtmdphd · 3 h

MT @RahulBanerjeeMD [6/3/24] To the editors of every journal ever - this is what "MRD" means in the year ≥2024 Minimal is an opinion, measurable is science at work. #ASCO24 #mmMRD #lymsm #MMsm #leusm @DrChrisHourigan @hemedoc x.com/RahulBanerjeeM…

RRahul Banerjee, MD, FACP@RahulBanerjeeMD · Jun 3, 2024

To the editors of every journal ever - this is what "MRD" means in the year ≥2024 🥂 Minimal is an opinion, measurable is science at work. #ASCO24 #lymsm #MMsm #leusm @DrChrisHourigan @hemedoc

482

Mike Thompson, MD, PhD, FASCO@mtmdphd · 3 h

Blood-Based Mass Spectrometry MRD Tracking (M-InSight) in Multiple Myeloma Patients from Clinical Trial NCT02513186 [Nov 2, 2023] Di Stefano et al. @BloodJournal #ASH23 ashpublications.org/blood/article/… #NCT02513186 #mmMRD #mmsm @SebiaUS

170

Mike Thompson, MD, PhD, FASCO@mtmdphd · 3 h

#ASH24 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702 #mmsm #bmtsm ash.confex.com/ash/2024/webpr…

162

Mike Thompson, MD, PhD, FASCO@mtmdphd · 3 h

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 meetings.asco.org/abstracts-pres… #NCT04108624 #mmsm #mmMRD

172

Mike Thompson, MD, PhD, FASCO@mtmdphd · 3 h

A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma myeloma.org/blog/dr-duries… #mmMRD #mmsm #ctsm @FDAOncology

mtmdphd's tweet image. A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma
myeloma.org/blog/dr-duries… #mmMRD #mmsm #ctsm @FDAOncology

150

Mike Thompson, MD, PhD, FASCO@mtmdphd · 3 h

Measurable Residual Disease and Decision-Making in Multiple Myeloma [Jan 6, 2024] @bdermanmd @Rfonsi1 Hematology/Oncology Clinics of North America sciencedirect.com/science/articl… #mmsm #mmMRD

mtmdphd's tweet image. Measurable Residual Disease and Decision-Making in Multiple Myeloma [Jan 6, 2024] @bdermanmd @Rfonsi1 Hematology/Oncology Clinics of North America
sciencedirect.com/science/articl… #mmsm #mmMRD

198

Mike Thompson, MD, PhD, FASCO@mtmdphd · 3 h

Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma [Jul 11, 2022] @bdermanmd @ajjakubowiak @mtmdphd @BloodCancerJnl nature.com/articles/s4140… #mmMRD #mmsm #openaccess

mtmdphd's tweet image. Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma [Jul 11, 2022] @bdermanmd @ajjakubowiak @mtmdphd @BloodCancerJnl nature.com/articles/s4140… #mmMRD #mmsm #openaccess

165

Mike Thompson, MD, PhD, FASCO@mtmdphd · 3 h

Clinician attitudes and practices toward measurable residual disease in multiple myeloma [Jun 7, 2020] @bdermanmd @jagoda_jasielec @ajjakubowiak Brit J Haematol ow.ly/3GSO50Cr8Mc #mmsm #mmMRD

mtmdphd's tweet image. Clinician attitudes and practices toward measurable residual disease in multiple myeloma [Jun 7, 2020] @bdermanmd @jagoda_jasielec @ajjakubowiak Brit J Haematol ow.ly/3GSO50Cr8Mc #mmsm #mmMRD

141

Mike Thompson, MD, PhD, FASCO@mtmdphd · 3 h

#mmMRD healthcare social media hashtag [Nov 21, 2020] Minimal/measurable residual disease (MRD) in multiple myeloma. Submitted by @bdermanmd to @symplur @healthhashtags symplur.com/healthcare-has… #mmsm

134

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML clinical-lymphoma-myeloma-leukemia.com/article/S2152-… #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

mtmdphd's tweet image. Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML clinical-lymphoma-myeloma-leukemia.com/article/S2152-… #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

172

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, & MGUS [2011] Karlsson et al. Clin Vaccine Immunol ow.ly/wTYz30iYZs3 #IDonc #mmsm #wmsm

mtmdphd's tweet card. Whereas patients with multiple myeloma (MM) have a well-documented susceptibility to infections, this has been less studied in other B-cell disorders, such as Waldenstrom's macroglobulinemia (WM) and...

196

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study [Jun 5, 2007] Vu et al. Clinical Infectious Diseases ow.ly/p8ii30qp0cl #Flu #IDonc #bmtsm

mtmdphd's tweet card. Abstract. Background. Oseltamivir is safe and effective in immunocompetent persons, and prophylactic use is recommended during influenza outbreaks. However

148

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

Respiratory tract infections in the pathway to multiple myeloma: a population-based study in Scandinavia [Dec 2006] @DrOlaLandgren et al. @Haematologica ow.ly/g08B30p6oej #IDonc #mmsm

mtmdphd's tweet card. Encounter with infectious antigens has been proposed to initiate the cascade of events associated with progression from premalignancy (monoclonal gammopathy of undetermined significance, MGUS) to...

179

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

UKMRC 1980-2002 Data: Infection & renal failure... ...cannot be accurately predicted by presenting prognostic features. All patients should be considered at high risk of death during induction therapy. [2005] Augustson et al. @JCO_ASCO ow.ly/BrQPV #mmsm #IDonc

mtmdphd's tweet card. A tenth of patients die within 60 days of diagnosis of MM. Infection and renal failure are the main direct causes of early mortality, which cannot be accurately predicted by presenting prognostic...

145

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

UKMRC 1980-2002 Data: 10% of MM pts die w/in 60 days of Dx. Infection & renal failure are the main direct causes of early mortality, which cannot be accurately predicted by presenting prognostic features [2005] Augustson et al. @JCO_ASCO ow.ly/BrQPV #mmsm #IDonc

175

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

Early mortality after Diagnosis of Multiple Myeloma: UKMRC 1980-2002 Data [2005] Augustson et al. @JCO_ASCO ow.ly/BrQPV #mmsm #IDonc

164

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

Infections are an important cause of morbidity & leading cause of death in myeloma [Oct 28, 2004] @RobertK68033234 & @VincentRK @NEJM ow.ly/O4Wju #mmsm #IDonc

259

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae [Jun 2002] Nordøy et al. Medical Oncology ow.ly/AswM30pK371 #mmsm #IDonc

mtmdphd's tweet image. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae [Jun 2002] Nordøy et al. Medical Oncology ow.ly/AswM30pK371 #mmsm #IDonc

128

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

RCT of IVIg as Px vs infection in plateau-phase myeloma [1994] Chapel et al. @thelancet ow.ly/sEFaz #mmsm #IDonc - 57% PV response

mtmdphd's tweet card. Patients with plateau-phase multiple myeloma have an increased risk of life-threatening bacterial infections and polyclonal humoral immune suppression. We conducted a randomised, double-blind,...

131

Mike Thompson, MD, PhD, FASCO@mtmdphd · 10 h

Lazarus et al. 1980 @amjmed ow.ly/x10Kg #mmsm #IDonc ~30% signif Ab response to immunization (14-valent pneumococcal) - low cost, low risk "...may be prudent medical practice to vaccinate patients with myeloma."

mtmdphd's tweet card. Pneumococcal vaccination: the response of patients with multiple myeloma

152